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Two local  factors which  may be responsible  for bone resorption  in  a  variety of 
chronic inflammatory and neoplastic diseases are the lymphokine osteoclast-activating 
factor (OAF) t  and  prostaglandins  (PGs)  (1,  2).  OAF  is  a  potent  mediator of bone 
resorption which is produced by phytohemagglutinin (PHA)-activated leukocytes and 
by certain neoplastic lymphoid cells (2, 3).  PGs, which are also potent mediators of 
bone  resorption  (4),  are  frequently  found  in  increased  concentrations  in  chronic 
inflammatory tissue (5). The interactions of these two factors may be very important 
in the localized bone destruction which occurs in diseases such as rheumatoid arthritis 
and periodontal disease and also around metastatic tumor deposits in bone. 
Most reports of the effects of PGs on the production of lymphokines have suggested 
that  PGs  are  inhibitory  (6-9).  However,  recently  we  showed  that  prostaglandin 
synthesis  was  necessary  for  OAF  production  by  activated  leukocytes  (10).  OAF 
production  was  inhibited  by  the  presence  of structurally  unrelated  inhibitors  of 
prostaglandin synthesis such as indomethacin, flufenamic acid, and R020-5720. OAF 
production was restored when PGs of the E series were added to activated leukocyte 
cultures together with indomethacin (10). Although these data showed that PGs were 
necessary for the  production of OAF  by stimulated  leukocytes, they did  not  show 
which  cells  in  the  leukocyte population were responsible  for OAF  production and 
which were responsible for the synthesis of PGs. 
The  presence  of both  lymphocytes and  monocytes is  required  in  the  activated 
leukocyte population  for OAF  release to occur  (11,  12). The experiments reported 
here were performed to determine the nature of the interaction between the monocyte 
and the lymphocyte in OAF production and the role of PGs in this interaction. They 
show that enriched activated lymphocytes produce OAF, but only in the presence of 
PGs of the E series which are released by adherent monocytes. 
Materials and Methods 
Leukocyte Culture.  Our  leukocyte  culture  technique  has  been  described  previously  (13). 
Normal human peripheral blood leukocytes were obtained from plateletpheresis  from normal 
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donors at the Connecticut Red Cross, Farmington, Conn. The leukocyte buffy coat was removed 
60 rain after the addition of 5 ml of 6% dextran to the plasma-leukocyte-erythrocyte mixture 
for acceleration of erythrocyte sedimentation. The leukocytes were suspended in BGJ medium 
(14)  (Grand Island Biological Co., Grand Island, N.Y.), centrifuged three times at  150 g for 5 
min to remove platelets, and resuspended in BGJ medium without added serum at a concen- 
tration of 2-2.5  ×  106 cells/ml in Falcon plastic tubes  (12  ×  75 mm) or tissue culture dishes 
(100  ×  20 mm) (Falcon Labware, Div. of Becton, Dickinson, & Co., Oxnard, Calif.). The cells 
were stimulated with  1% phytohemagglutinin-M (PHA-M) (Grand Island Biological Co.) and 
cultured for 24-72  h  at 37°C in an atmosphere of 5% CO2 in air. At the end of culture, the 
supernates were collected by careful aspiration and frozen at -20°C until the OAF assay. The 
remaining leukocytes were pulsed with [aH]thymidine (New England Nuclear, Boston, Mass.) 
or all-amino acids  (New England  Nuclear)  for 4-6  h  and  the  incorporation of 3H  into the 
trichloroacetic acid-insoluble cell fraction was measured. 
Preparation of Adherent Monocytes.  Leukocytes were collected in BGJ medium supplemented 
with 4  mg/ml of bovine serum albumin  (BGJ, BSA4, Reheis Chemical Co., Div. of Armour 
Pharmaceutical Co., Chicago, Ill.)  in a similar manner to that described above. After 24-48 h, 
when adherent  ceils were observed under phase-contrast  microscopy, nonadherent  cells were 
removed by vigorous pipetting. The adherent cells were evaluated for viability by trypan blue 
exclusion, cytoplasmic spreading by Wright's staining, phagocytotic ability by uptake of latex 
beads  (15) (0.8  microns, Sigma Chemical Co.,  St.  Louis,  Mo.),  and  for nonspecific esterase 
activity (16). More than 95% of the adherent cells were viable, >85% of the viable cells were 
capable  of phagocytosis,  and  >92%  of the  cells  showed  nonspecific  esterase  activity  and 
cytoplasmic spreading.  These adherent  cells were designated enriched monocytes. Using this 
method,  1.5  2.0  X  105/ml  of monocytes were  recovered from  each  leukocyte culture.  The 
enriched  monocytes were  detached  from  the  bottom  of dishes  by  incubating with  trypsin- 
EDTA  (1X,  Grand  Island  Biological Co.)  for  10-15  min,  suspended  in  the  medium,  and 
counted on a  hemocytometer. Enriched monocyte culture was carried out  in BGJ, BSA4  for 
48-72  h.  At  the  end  of this  period,  the  monocyte  culture  media  was  harvested  and  the 
monocytes were detached and recombined with the nonadherent  enriched lymphocytes. This 
mixed  population  of cells  was  then  cultured  in  BGJ  medium  in  a  similar  manner  to  the 
leukocyte cultures to assess DNA and protein synthesis and the production of OAF by the cells. 
Preparation of Nonadherent Lymphocytes.  Nonadherent  cells obtained after 24-48 h  of culture 
on plastic surfaces were washed three times, resuspended in BGJ, BSA4, replated on new dishes, 
and cultured for a further 24 h. After that, the cells which had still not adhered to the dishes 
were  again  replated  on  new  dishes  and  cultured  for  a  further  24  h.  The  final  resulting 
nonadherent cells were designated enriched nonadherent  lymphocytes. They were cultured in 
BGJ in a similar manner to that of the leukocytes (see above). 
Drugs.  Indomethacin (Sigma Chemical Co.), D-1,6-chloro-a-methyl-carbazole-z-acetic acid 
(R020-5720,  Hoffman-LaRoche Inc.,  Nutley,  N. J.),  ftufenamic acid  (Aldrich Chemical Co. 
Inc., Milwaukee, Wis.), and prostaglandin Ex, E2, Fla, and F2a (Sigma Chemical Co.) were all 
dissolved in 95% ethyl alcohol and added to the cultures to the desired concentration 2 h before 
activation of cells with PHA. An identical concentration of ethyl alcohol was added to some 
control cultures. There was no detectable difference in control cultures to which alcohol had 
been added compared with those to which it was not added. 
Bioassay for Bone Resorbing Activity As a Result of OAF.  Bone resorbing activity, as a result of 
OAF in the leukocyte culture supernates, was assessed  by methods which have been previously 
......  45  described (13, 17). Pregnant mice were rejected subcutaneously with 0.05  mCl of  Ca on the 
16th  d  of gestation.  On  the  next  day,  the  fetuses  were  removed  from  the  mothers  and 
mineralized shafts on their radii and ulnae were dissected free from surrounding soft tissue and 
the  cartilagenous  ends.  These  bones  were  cultured  in  BGJ  medium  for  24  h  to  allow  for 
exchange of loosely complexed 45Ca with stable calcium in the medium. The bones were then 
cultured either in the test  media containing the cell culture supernates to be assayed or in the 
control  media. The cell culture supernates  were diluted  1:1  or  1:3 with  fresh  BGJ  medium 
before assay for bone resorbing activity. Bone resorbing activity of OAF was expressed as the 
percent of total radioactivity released from the bone into the culture medium during the culture 
period or as the ratios of 45Ca release from the test  bones compared with the bones cultured in 
control media. The results were expressed as means and standard errors for four pairs of bone 340  MONOCYTES  REGULATE  OSTEOCLAST-ACTIVATING  FACTOR  PRODUCTION 
TABLE  I 
Effects of Prostaglandin Synthetase Inhibitors on [ 3  H] Thymidine ( { 3  H] TdR ) and 3H-Amino Acid (3  H- 
AA ) Incorporation and OAF and PG Production by Leukocyte Cultures 
OAF produc- 
tion:~ 
PHA  Inhibitors  [aH]TdR incorpora-  aH-AA incorpora-  (treated/control  PGE 
tion*  tion*  ratios of 4~Ca re- 
lease) 
I%  IO #M  cprn  cpm  ng/ml 
-  --  1,868 +  168  452  _  77  0.80 ±  0.07  2.00 
-  Indomethacin  2,432  ±  261  806  ±  91  1.07 ±  0.05  ND 
-  R020-5720  2,310  ±  241  517  ±  57  1.05 ±  0.08  0.07 
-  Flufenamic acid  1,562 ±  279  466 _  52  1.08 ±  0.13  ND 
+  --  27,767  ±  1,536§  2,625  ±  211§  1.97 +  0.26§  12.80 
+  Indomethacin  22,889  --.  1,835§  2,319  +  103§  1.03 ±  0.02[I  0.34 
+  R020-5720  27,081  _  1,516§  2,512  ±  367§  0.98  +  0.16  H  0.80 
+  Flufenamic acid  26,245  ±  1,551§  2,510  ±  285§  1.07 ±  0.151]  0.52 
ND, not detectable. The leukocytes were cultured for 48 h  in BGJ medium without serum supplemen- 
tation. 
* Values expressed as means ±  SEM for three leukocyte cultures. 
:~ Values expressed as means ±  SEM for four pairs of bone cultures. 
§ Significantly greater than corresponding control, P <  0.05. 
][ Significantly different from stimulated cultures without inhibitor, P <  0.05. 
cultures. Statistical differences were analyzed using Student's t test. 
Diafiltration of Media.  In some experiments, prostaglandins were removed from cell culture 
supernates  by  diafihration  across  Amicon  UM-2  membranes  (Amicon Corp.  Scientific  Sys. 
Div.,  Lexington,  Mass.)  using  continuous  replacement  with  10  vol  of  BGJ  media.  These 
membranes have a nominal molecular weight cutoffof 1,000 dahons. All steps were carried out 
at 4°C. 
Prostaglandin Measurement.  The  amount  of total  PGE and total  PGF  in culture supernates 
was measured according to the method of Zurier and Sayadoff (18).  In brief, after addition of 
3H-PGEx and-PGF2~ (New England Nuclear) for calculation of recovery, the culture supernates 
were  extracted  twice with  2:1  ethylacetate:  cyclohexane,  and  the extracts  were  dried  under 
nitrogen. The residues were vortexed in 0.4 ml of 10% methanol in 60:40 benzene-ethylacetate 
and chromatographically separated on silicic acid column. PGE and PGF in the samples were 
sequentially eluted  with  3%  and  30%  methanol  in  60:40  benzene:ethyl acetate,  respectively. 
The  fractions  were  then  dried  and  reconstituted  with  0.2  M  phosphate  buffer  (pH  7.0) 
containing 1% rabbit serum.  Radioimmunoassays for PGE and PGF content were carried out 
in  the  manner previously  described  (19).  Measurements  were corrected  for  final recovery of 
added tritiated PG, which averaged 40%, 
Results 
Effects of PGs Synthesis  Inhibitors  on [3H] Thymidine and 3H-Amino Acid Incorporation, OAF 
Production,  and PGs Synthesis  by  Leukocytes.  PHA-stimulated  leukocytes  incorporated 
10-  to  15-fold  more  3H-amino  acids  than  corresponding  unstimulated  leukocytes 
(Table I). This increased incorporation  was not affected by the addition  of indometh- 
acin  (20,  21),  R020-5720  (22),  and  flufenamic  acid  (21),  known  inhibitors  of  PGs 
synthesis (Table I). In the same cultures, however, these inhibitors completely blocked 
OAF  production  by  the  stimulated  cells  (Table  I),  as  we  have  reported  previously 
(10).  In  parallel  with  this,  PGE  content  of the stimulated  leukocyte  media  was  also 
decreased to undetectable  amounts  by the addition  of these prostaglandin  synthetase 
inhibitors  (Table  I).  Unstimulated  leukocytes  cultured  with  the  drugs  showed  no TOSHIYUKI YONEDA AND GREGORY  R.  MUNDY 
TABLE  II 
Effects of Varying Concentrations of lndomethacin on [3H] TdR and 3  H-AA Incorporation 
and OAF Production by PHA-Stimulated Leukocytes Cultured  for 48 h 
341 
OAF production~ 
Concentration  [3H]TdR  incorpora-  3H-AA incorpora-  (treated/control ratios 
tion*  lion*  of 4~Ca release) 
cpm  cpm 
0  2,229 --- 272  918  __ 90  1.39 +  0.03 
lO,aM  3,724  +_  142  1,372 ___  Ill  1.04 +  0.02§ 
l ,aM  9,895  ::t: 124  1,258 ::t: 106  1.05 ___ 0.03§ 
0.1 ,aM  7,653 _.+ 437  1,499 _.  136  1.I1  +  0.03§ 
10 nM  3,415  +  174  677  :t: 88  1.17 +  0.03§ 
1 nM  2,083  +  413  671  +  38  1.17 __. 0.03§ 
For experimental details see Materials and Methods. 
* Values expressed as means  _  SEM for three leukocyte cultures. 
:I: Values expressed  as means  +  SEM for four pairs of bone cultures. 
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FIG.  I.  Time-course of leukocyte  activation and OAF production in the presence or absence of 10 
,aM indomethacin. Three leukocyte  cultures, with or without indomethacin, were assessed at each 
time point  of 24,  48,  and  72  h.  O---O,  leukocytes  +  PHA; 0-'-'---0, leukocytes  +  PHA  + 
Indomethacin. A, [3H]TdR  a  incorporation; B,  H-AA incorporation; and C, OAF production. 
significant  changes  except  for  decreased  PGE  synthesis  (Table  I).  Indomethacin,  a 
potent  inhibitor of PGs synthesis, blocked OAF  production  at concentrations of 1 nM 
to  10  #M  (Table  II).  Fig.  1  shows  a  time-course  of leukocyte  activation  and  OAF 
production  in  the  presence  or absence  of indomethacin  (10 #M).  Indomethacin  did 
not affect leukocyte activation as assessed by the incorporation of radioactive isotopes 
into  DNA  and  protein  by  the  stimulated  cells,  whereas  OAF  production  was  com- 
pletely inhibited  by indomethacin  through  the entire culture period  (Fig.  1).  Flufen- 
amic acid and R020-5720 demonstrated  the same time- and concentration-dependent 
inhibition on OAF  production  as indomethacin  (data  not shown). 
Effect of PGs Synthesis Inhibitors on Biological Activity of OAF.  To exclude the possibility 
that  these drugs were inhibiting the biological activity of OAF  rather than  inhibiting 
OAF  production,  bones were cultured  in OAF-containing  media with  the inhibitors 
and bone resorbing activity was measured. There was no inhibition of bone resorption 342  MONOCYTES REGULATE OSTEOCLAST-ACTIVATING FACTOR  PRODUCTION 
TABLE III 
Effect of PGs Synthesis Inhibitors on Bone Resorbing Activity As a Result of 
OAF 
PGs synthesis inhibitors added to OAF-  72-h 4~Ca release 
containing media  (treated/control)* ratios 
I  O  I~M 
None  1.50 :k 0.08 
Indomethaciu  1.52 +  0.11 
R020-5720  1.76 +  0.14 
Flufenamic acid  1.66 +  0.06 
OAF was produced by stimulated leukocytes  cultured for 48 h. The inhibitors 
of PGs synthesis were added directly to the OAF-containing media and the 
samples were assayed for bone resorbing activity. 
* Values are means +  SEM for four pairs of bone cultures. 
TABLE  IV 
Effects of Indomethacin, R020-5720 and Flufenamic Acid on OAF Production 
When Added to Leukocyte Cultures 24 h after the Stimulation of the Cells with 
PHA 
OAF production* 
PGs synthesis inhibitors  (treated/control ratios of 4~Ca re- 
leased) 
IO ~M 
None  2.68 +  0.17 
lndomethacin  2.97 ±  0.47 
R020-5720  2.76 ±  0.13 
Flufenamic acid  1.88 ±  0.08 
* Values are means +  SEM for four pairs of bone cultures. 
by  10/~M  indomethacin, R020-5720,  or  flufenamic acid  (Table III).  Furthermore, 
when the inhibitors were added to leukocyte cultures 24 h after the stimulation of the 
cells with PHA, inhibition of OAF production or diminution of OAF effects on bone 
were  not observed with indomethacin or  R020-5720  (Table IV).  Slightly less OAF 
was produced in the presence of flufenamic acid (Table IV). 
Requirement  of the  Presence of Monocytes for OAF Production  by PHA-Stimulated Lympho- 
cytes.  PHA-stimulated nonadherent enriched  lymphocytes showed  an  increase  in 
[3H]thymidine and  3H-amino acid  incorporation as  compared  with  corresponding 
unstimulated lymphocytes, whereas OAF was not produced by these cells at all (Table 
V).  However,  as  suggested  previously (11,  12),  this failure of OAF production was 
restored by reconstitution of stimulated nonadherent enriched lymphocytes (2.0  × 
106 cells/ml) with  enriched monocytes (1.2  ×  10  ~ cells/ml)  (Table V).  Monocytes 
(Table  V)  and  unstimulated  lymphocytes  (data  not  shown)  incorporated  little 
[3H]thymidine or 3H-amino acids and produced no OAF. 
OAF Production by PHA-Activated Lymphocytes  Cultured  with  Conditioned Media of Mono- 
cytes.  The  data  shown  in  Table V  indicate that  activated  enriched  lymphocytes 
require the presence of monocytes and/or soluble factors derived from monocytes to 
produce OAF. To examine this further, nonadherent PHA-stimulated lymphocytes 
(1.5  X  106 cells/ml) were cultured with monocyte-conditioned medium (MCM)  for TOSHIYUKI YONEDA  AND  GREGORY  R.  MUNDY  343 
TABLE V 
Requirement of the Presence of Monocytes  for OAF Production by PHA-Activated Lymphocytes (act. 
tc) 
OAF productions 
act. lc  Monocytes  [ZH]TdR  incorpora-  aH-AA incorpora-  (treated/control ra- 
tion*  tion*  tios of*~Ca release) 
cpm  cpm 
+  4,092 +  339  1,671  +  60  0.86 +  0.18 
+  +  4,362 ±  91  1,332 ±  44  1.80 +  0.33§ 
+  56 +  2  69 +  4  0.84 ±  0.|5 
Unseparated  PHA-acti-  6,633 +  226  2,769 +- 250  2.37 +_ 0.34§ 
vated leukocytes 
Adherent and nonadherent cells were separated described in Materials and Methods. The adherent 
monocytes were cultured at a 2 ×  105-cell/ml concentration. The nonadherent  lymphocytes were 
cultured at a 1.5 ×  106-cell/ml concentration.  Act. lc, PHA-activated lympocytes. 
* Values are means +  SEM for three leukocyte cultures. 
:~ Values are means -  SEM for four pairs of bone cultures. 
§ Significantly >1.0, P < 0.05. 
48  h  (Table VI).  MCM  was obtained from  the 48-h  culture of enriched  monocytes 
(2.0  ×  10 ~ cells/ml) treated with or without  indomethacin  (10 ~M)  and diluted  1:1 
with fresh BGJ. Activated enriched lymphocytes that were depleted of monocytes did 
not  produce OAF  by themselves,  but  released OAF when  they were  cultured  with 
MCM  (Table VI).  On  the other hand,  when  activated enriched  lymphocytes were 
cultured with conditioned medium from monocytes treated with indomethacin, they 
failed  to  produce  OAF  (Table  VI).  Neither  MCM  nor  conditioned  medium  from 
monocytes  treated  with  indomethacin  contained  OAF.  There  was  no  significant 
change in the incorporation of [ZH]thymidine or 3H-amino acids into the cells cultured 
with  or  without  MCM  (Table  VI).  The  concentration  of PGE  in  the  MCM  was 
measured  using  a  radioimmunoassay.  The  conditioned  media from  monocytes cul- 
tured  with  indomethacin  contained  less  PGE  (0.08  ng/ml)  than  the  media  from 
monocytes cultured without  indomethacin  (1.6 ng/ml). 
OAF Production by  PHA-Activated  Lymphocytes Cultured in  Media  Containing Exogenous 
PGE1 or PGE2.  The previous results show that soluble factors released by monocytes 
are required for activated lymphocytes to synthesize OAF and  it seemed likely that 
these soluble factors may be PG. To determine if PGs could obviate the necessity for 
the presence of monocytes for OAF production by lymphocytes, PGE1 and PGE2 (0.1 
ktM)  were added directly to activated enriched  lymphocyte cultures  (Table VII). In 
this experiment, the supernates of stimulated  lymphocyte cultures were  assayed for 
OAF content and immunoreactive PGE concentrations before and after diafihration 
across an Amicon UM  2  membrane,  a  procedure which was required to remove the 
exogenously added PGE1 or PGE2 before assay for OAF activity. To test the efficacy 
of diafiltration, the same concentrations  of PGE1  and  PGE2  were  added to  control 
media, diafiltered, and assayed for bone resorbing activity and immunoreactive PGE 
in  a  similar  manner.  The  concentration  of  PGE  in  the  diafihered  lymphocyte 
supernates and in the control media was <0.1  ng/ml, which was <1/400  that of the 
nondiafihered supernates and control media to which  PGE1  and  PGE2 were added. 
This indicates that  most  PGE in the supernates and the control media was removed 344  MONOCYTES  REGULATE  OSTEOCLAST-ACTIVATING  FACTOR  PRODUCTION 
TABLE  VI 
Effect of MCM on Production of OAF and Incorporation of [aH] TdR and 3  H-AA by PHA Lymphocytes 
Conditions of leukocyte culture 
MCM  +  act. lc  MCM  Indo 
OAF production~ 
[aH]TdR incorpora-  aH-AA incorpora-  (treated/control ra- 
tion*  tion*  tios of 4'~Ca release) 
cpm  cpm 
+  4,089  ±  60  4,635  ±  227  1.02 ±  0.13 
+  +  3,268  ±  501  4,814  ±  24  2.52  +  0.45§ 
+  +  3,512  ±  566  4,924  ±  387  1.09 ±  0.09 
+  0.97  ±  0.O3 
+  1.01  +  0.03 
The methods of preparation of lymphocyte and monocyte cultures are indicated in Methods. Indometh- 
acin (10/~M) was added to the monocytes and the media harvested of 3 d of culture. The duration of the 
lymphocyte culture was 48 h. The bones were cultured for 72 h. 
MCM  +  Indo, media from monocytes cultured with indomethacin (10/LM). 
* Values are means ±  SEM for three lymphocyte cultures. 
:~ Values are means ±  SEM for four pairs of bone cultures. 
§ Significantly greater than corresponding control, P <  0.01. 
TABLE  VII 
Elaboration of OAF by act. lc. with PGE1 or PGE2 Added Exogenously 
act. Ic  PGEz  PGE2 
OAF production* 
4SCa release (treated/control ratio) 
Before diafihration  After diafiltration 
O.I#M  O. ItLM 
+  --  0.93  -  0.07 
+  +  2.81  +  0.29~  1.86 +  0.24:1: 
+  +  2.83  ±  0.301:  1.36 --. 0.03:t: 
+  1.34 ±  0.03:~  0.92  ±  0.12 
+  1.31  +  0.03:~  0.95  ±  0.13 
Experimental details are indicated in Methods. 
* Values are means +  SEM for four pairs of bone cultures. 
:~ Significantly >1.0, P< 0.05. 
during  the  diafiltration  process.  No  bone  resorbing  activity  was  present  in  these 
solutions after diafihration  across the Amicon  UM  2  membrane  (Table VII), indicat- 
ing  that  bone  resorbing  activity  present  in  the  lymphocyte  culture  supernates  after 
this procedure  could not  be ascribed to PGs.  In contrast,  the supernates  of activated 
enriched lymphocytes  depleted  of monocytes  cultured  with exogenously  added  PGEt 
or PGE2 (0.1/~M) showed significant bone resorbing activity after diafiltration  (Table 
VII).  When  activated  lymphocytes  were  cultured  with  1  nM  PGEa  (approximately 
the amount  detected in the MCM),  slight but significant recovery of OAF  production 
was observed  (treated/control  ratio of 45Ca release  1.19  +  0.02). 
Failure of PGE to Augment  OAF Activity.  Although  the results shown  in Table  VII 
indicate  that OAF  was  produced  by activated  lymphocytes  cultured  in the presence 
of PGE1  or PGE2,  and  that  these exogenously  added  prostaglandins  could substitute 
for the presence of monocytes  in the leukocyte  population  as  far as OAF  production 
was  concerned,  it  might  still  be  possible  that  PGE  augmented  OAF  activity  rather 
than OAF  production.  Removal  of PGs during diafiltration indicates this explanation TOSHIYUKI YONEDA  AND GREGORY  R.  MUNDY  345 
TAaLE  VIII 
The Failure of PGEa to Augment the Biological Activity of OAF 
PGEI 
OAF-containing 
media  0.1 btM  1 nM 
OAF activity* 
(treated/control ratios of 
4~Ca release) 
+  1.72 +  O.06 
+  +  1.77 +  0.O7 
+  +  1.74  ±  0.1 
+  1.20 ±  0.05 
+  1.04 _  0.08 
OAF was produced by stimulated leukocytes cultured  for 48  h.  PGE1  was 
added directly to the OAF-containing media and the samples were assayed 
for bone resorbing activity. 
* Values are means ±  SEM for four pairs of bone cultures. 
is unlikely. To exclude this possibility further, we added PGE1 in varying concentra- 
tions to submaximal doses of OAF (Table VIII). We found no augmentation of OAF 
activity. 
Discussion 
In the present study, we have found that: (a) OAF was not produced by stimulated 
lymphocytes unless monocytes coexisted with them in the leukocyte population (Table 
V);  (b) OAF was produced by stimulated lymphocytes cultured with MCM, but not 
with conditioned medium from monoeytes treated with indomethacin (Table VI); (c) 
PGE concentrations were  much  higher in  MCM  (1.6  ng/ml)  than  in  conditioned 
media  from  monocytes  treated  with  indomethacin  (0.08  ng/ml);  (d)  OAF  was 
produced by stimulated enriched lymphocytes cultured with exogenously added PGE1 
or PGE2 (Table VII); and (e) PGEa was unable to enhance OAF activity (Table VIII). 
These findings lead us to conclude that PG of the E series synthesized and released by 
monocytes are required for activated lymphocytes to produce OAF. 
The  fact  that  nonadherent  enriched  lymphocytes  depleted  of monocytes were 
capable  of producing OAF  in  the  presence of MCM  or exogenously added  PGEa 
(Tables VI and VII) indicates that the lymphocyte is the cell which is responsible for 
OAF production. This confirms earlier data which showed that OAF production was 
markedly diminished when PHA-stimulated leukocytes were irradiated (11). Because 
lymphocytes are much more sensitive to irradiation  than  monocytes, these authors 
suggest that reduction in OAF as lymphocytes were depleted indicates that lympho- 
cytes were responsible for OAF  production.  However, this evidence is  indirect and 
there can be other interpretations of the data. Now we have shown that lymphocytes 
depleted of monocytes are capable of producing OAF, this is direct evidence that the 
lymphocyte is the cell source of OAF production. 
The amounts of OAF which was produced by PHA-activated nonadherent enriched 
lymphocytes cultured with exogenously added  PGEa was not  significantly different 
from that  produced by activated lymphocytes cultured with MCM  or unseparated 
leukocytes. Thus, it is likely that PGE by itself is sufficient to replace the requirement 
of the presence of monocytes for OAF production by activated lymphocytes. However, 
we cannot exclude the possibility that some other monocyte-derived factor, as well as 
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Most reports of the effects of PGs on the secretion of inflammatory mediators have 
suggested that  PGs are inhibitory. For example, the release of histamine by human 
and monkey mast cells and/~-glucuronidase and other lysosomal hydrola~es by human 
neutrophils is blocked by PGE (23).  Similarly, the secretion of lymphokines such as 
macrophage migration  inhibition  factor (7)  and  leukocyte inhibitory factor (9)  are 
also suppressed by PGE. Moreover, Gordon et al.  (8) have shown that PGE1 inhibits 
migration inhibition factor secretion by cultured guinea pig peritoneal exudate cells 
which consist of 60-80% macrophages and had been already found to produce PGE1 
when  cultured  in  vitro  (24).  Therefore, Morley (6)  has proposed a  hypothesis that 
lymphokines activate macrophages to produce PGE,  which  in  turn  inhibit  further 
lymphokine production by a negative feed-back mechanism. This inhibitory effect of 
PGE on lymphokine production has been considered to be a self-protective mechanism 
from the progressive development of unregulated immune responses (23). In contrast, 
we  have  shown  here  that  the  presence of PGE  is  required  for  the  production  of 
another  lymphokine,  OAF.  Also,  the  evidence  reported  here  indicates  that  PGE 
resorbs bone not only directly but also indirectly by enhancing OAF production upon 
the appropriate stimulation. 
As PGE has been known to stimulate intracellular cyclic AMP accumulation, the 
enhancing  effects of PGE on  OAF  production  may be  mediated  by cyclic AMP. 
However, Koopman et al. (7), Bourne et al. (23), and Lomnitzer et al. (9) have shown 
that isoproterenol and PGE (both stimulators of adenylate cyclase), theophylline, and 
other methylxanthine derivatives (phosphodiesterase inhibitors), and dibutyryl cyclic 
AMP  (an analogue of the endogenous nucleotide) all inhibit  histamine release and 
lymphokine production together with elevation of intracellular cyclic AMP. It seems 
reasonable to suggest that cyclic AMP may be a negative modulator of inflammation 
and immunity in these circumstances. However, the situation may be different with 
OAF production. As PGs are necessary for OAF production, it is possible that in this 
case intracellular cyclic AMP  enhances  rather than  inhibits  the production of the 
lymphokine. Studies are now in progress to investigate the relationship between cyclic 
AMP and OAF production. 
Of particular interest is the role of monocytes in OAF production. In the present 
study,  monocytes  have  behaved  as  helper  cells  by  releasing  PGs  to  allow  OAF 
production by activated lymphocytes. This is another mechanism by which monocytes 
can  influence the process of bone resorption. Other work from our laboratory has 
demonstrated that monocytes directly resorb both devitalized bones by a mechanism 
which  is  not  mediated  by the action of osteoclasts (25)  and  live bones through  an 
osteoclast-mediated mechanism which is prostaglandin-dependent  (26).  There is also 
other evidence which suggests that monocytes and macrophages synthesize and release 
PGs (27-29), collagenase (30), and hydrolytic enzymes (31), which are all capable of 
resorbing bone or degrading bone matrix.  It is also possible that circulating mono- 
nuclear cells may transform or differentiate into osteoclasts (32). Thus, it seems likely 
that monocytes possess multifunctional capacities in the bone resorption process and 
may reveal each function separately or synergistically depending on the environmental 
conditions. 
Although the PGs synthesis inhibitors blocked OAF production completely, they 
showed  no consistent  effect on  the  incorporation of [3H]thymidine and  3H-amino 
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[3H]thymidine, [3H]uridine, and [14C]leucine incorporation by PHA-stimulated lym- 
phocytes were not affected by indomethacin, phenylbutazone, and aspirin. Therefore, 
it is clear that PGs are not essential for the stimulation of lymphocytes (10, 33). Thus, 
the pathway or mechanism of OAF production in the lymphocyte may be different 
from that of cell transformation. 
In the experiment shown in Table II, [3H]thymidine and 3H-amino acid incorpo- 
ration by the stimulated cells increased after the addition of indomethacin, in spite of 
decreased OAF  production.  Similar results  have been  described by Goodwin et  al 
(34).  They demonstrated  the  presence of prostaglandin-producing  suppressor  ceils 
which  adhered  to  glass-wool  in  patients  with  Hodgkin's  disease  (34)  and  normal 
persons  (35).  Our  leukocytes were obtained  from  normal  human  peripheral  blood 
obtained from plateletpheresis donations. We observed an increase in incorporation 
of radioactive  materials  into  lymphocytes after adding  indomethacin  in  only one 
experiment of many. This finding in one experiment and  discrepancy from others' 
results is unexplained, but may be a result of differences in the source of leukocytes or 
by differences in cell separation techniques. 
The  incorporation of [3H]thymidine and  all-amino  acids  into  PHA-stimulated, 
nonadherent  enriched  lymphocytes was  significantly  less  than  that  of stimulated 
unseparated leukocytes (Table V). Reconstitution of the lymphocytes with enriched 
monocytes did not increase the incorporation to that of unseparated leukocytes (Table 
V).  There  are  a  number  of possible  explanations.  We  cannot  be  sure  that  the 
proportions of T  lymphocytes, B  lymphocytes, and  monocytes are the same  in  the 
reconstituted population as in the unseparated cells. There may also have been some 
impairment of mitogen sensitivity or vitality of some of the cells during the process of 
leukocyte separation.  Using different separation  techniques others have found that 
reconstituted cells incorporated more [aH]thymidine than unseparated cells (11). 
Our findings show that the presence of prostaglandins are necessary for OAF to be 
produced  by  activated  lymphocytes. The  usual  source of PGs  is  likely  to  be  the 
monocyte. However, it is also likely that PGs produced by neoplastic cells (36, 37) or 
by chronic inflammatory cells (5, 38, 39) also modulate OAF production by lympho- 
cytes. Thus, PGs produced by neoplastic or inflammatory cells may influence bone 
resorption directly by activating osteoclasts and indirectly through their influences on 
OAF production. 
Summary 
Osteoclast-activating  factor  (OAF),  a  powerful  stimulator  of osteoclastic  bone 
resorption, is released by peripheral blood mononuclear cells on exposure to phyto- 
hemagglutinin  (PHA)  or  a  specific  antigen  to  which  the  leukocytes  have  been 
previously exposed. Both lymphocytes and monocytes are required in the leukocyt  e 
population  for OAF  release  to occur.  In  this  study  we  examined  the  relationship 
between the lymphocyte and monocyte in OAF production. Biological activity, as a 
result of OAF, was assessed by a bioassay based on the release of previously incorpo- 
rated 45Ca from fetal rodent long bones in organ culture. We found that an enriched 
lymphocyte population depleted of monocytes by serial adherence does not  release 
OAF  after stimulation  with  PHA,  although  the  cells  are  activated  as  assessed  by 
[3H]thymidine and 3H-amino acid incorporation. When conditioned media harvested 
from adherent cells which did not contain OAF was added to the enriched lympho- 348  MONOCYTES  REGULATE  OSTEOCLAST-ACTIVATING  FACTOR PRODUCTION 
cytes, OAF release occured. Media harvested from adherent cells which were cultured 
with  indomethacin  (10 #M), an inhibitor of prostaglandin  synthesis, did not permit 
OAF release by activated lymphocytes. When PGE1 and PGE2 (0.1/~M)  were added 
exogenously  to  the  enriched  lymphocyte  population,  OAF  release  occurred  after 
stimulation with PHA. These results indicate that,  (a) the activated lymphocyte is the 
cell  of origin  of OAF,  (b)  prostaglandins  produced  by  monocytes are  necessary  for 
OAF  production  by  activated  lymphocytes,  and  (c)  monocyte  prostaglandins  can 
influence bone resorption indirectly by regulating OAF production as well as directly 
by osteoclast activation. The interactions of OAF and prostaglandins at bone resorbing 
sites may be important  in inflammatory and neoplastic diseases associated with bone 
destruction. 
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